Loss of Heterozygosity clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
A Study of the Experimental Medicine Rucaparib for Recurrent Non-small Cell Lung Cancer
open to all eligible people
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sacramento, California and other locations